Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: A cost/utility analysis using an analytic decision model

Thrombosis Journal

Volumn 11, Issue 1, 2013, Pages

  Nshimyumukiza, Léon ^a   Duplantie, Julie ^a   Gagnon, Mathieu ^a   Douville, Xavier ^a   Fournier, Diane ^a   Lindsay, Carmen ^b   Parent, Marc ^b   Milot, Alain ^a,b   Giguère, Yves ^a,b   Gagné, Christian ^a   Rousseau, François ^a,b   Reinharz, Daniel ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Anticoagulation; Atrial fibrillation; Cost utility; CYP2C9; Dabigatran etexilate; Simulation; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; DABIGATRAN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CEREBROVASCULAR ACCIDENT; COST UTILITY ANALYSIS; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; PHARMACOGENETICS; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; THROMBOEMBOLISM;

EID: 84880183125     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-11-14     Document Type: Article

References (64)

1. Healey JS, Parkash R, Pollak T, Tsang T, Dorian P, CCS Atrial Fibrillation Guidelines Committee Canadian cardiovascular society atrial fibrillation guidelines 2010: etiology and initial investigations. Can J Cardiol 2011, 27(1):31-37. 10.1016/j.cjca.2010.11.015, 21329860, CCS Atrial Fibrillation Guidelines Committee.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: anti-thrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146(12):857-867. 10.7326/0003-4819-146-12-200706190-00007, 17577005.
3. Poli D, Antonucci E, Grifoni E, et al. Stroke risk in atrial fibrillation patients on warfarin: predictive ability of risk stratification schemes for primary and secondary prevention. Thrombo Haemost 2009, 101(2):367-372.
4. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007, 167(13):1414-1419. 10.1001/archinte.167.13.1414, 17620536.
5. Krynetskiy E, McDonell P. Building individualized medicine: prevention of adverse reactions to warfarin therapy. J Pharmacol Exp Ther 2007, 322(2):427-434. 10.1124/jpet.106.117952, 17496169.
6. Lip GYH, Wrigley BJ, Pisters R. Anticoagulation versus placebo for heart failure in sinus rhythm. Cochrane Database Syst Rev 2012, (Issue 6):Art. No.: CD003336.
7. Palareti G, Legnani C, Guazzaloca G, Lelia V, Cosmi B, Lunghi B, Marchetti G, Poli D, Pengo V, ad hoc Study Group of the Italian Federation of Anticoagulation Clinics* Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol 2005, 129(1):72-78. 10.1111/j.1365-2141.2005.05417.x, 15801958, ad hoc Study Group of the Italian Federation of Anticoagulation Clinics*.
8. Adcock DM, Koftan C, Crisan D, Kiechle FL. Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation. Arch Pathol Lab Med 2004, 128(12):1360-1363.
9. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007, 7(2):99-111. 10.1038/sj.tpj.6500417, 16983400.
10. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007, 121(1):23-34. 10.1007/s00439-006-0260-8, 1797064, 17048007.
11. Thomas FJ, Mcleod HL, Watters JW. Pharmacogenomics: the influence of genomic variation on drug response. Curr Top Med Chem 2004, 4(13):1399-1409.
12. Tan G-M, Wu E, Lam YY, Yan BP. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics J 2010, 11(3):439-448.
13. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF, Couma-Gen Investigators Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007, 116(22):2563-2570. 10.1161/CIRCULATIONAHA.107.737312, 17989110, Couma-Gen Investigators.
14. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2007, 25(1):45-51.
15. Reddy P, Atay JK, Selbovitz LG, Connors JM, Piazza G, Block CC, Arpino PA, Berliner N, Hutter AM, Fischer MA, Kuter D, Weitzman J, Sherwood GK, Almozlino A, Giugliano RP. Dabigatran: a review of clinical and pharmacoeconomic evidence. Crit Pathw Cardiol 2011, 10(3):117-127. 10.1097/HPC.0b013e3182315c03, 21989032.
16. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361(12):1139-1151. 10.1056/NEJMoa0905561, 19717844, RE-LY Steering Committee and Investigators.
17. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011, 154(1):1-11. 10.7326/0003-4819-154-1-201101040-00289, 21041570.
18. Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, Cowie MR. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 2012, 98(7):573-578. 10.1136/heartjnl-2011-300646, 3308473, 22422743.
19. Langkilde LK, Bergholdt AM, Overgaard M. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark. J Med Econ 2012, 15(4):695-703. 10.3111/13696998.2012.673525, 22397590.
20. Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, Plumb JM. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011, 105(5):908-919. 10.1160/TH11-02-0089, 21431243.
21. You JHS, Tsui KKN, Wong RSM, Cheng G. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS ONE 2012, 7(6):e39640. 10.1371/journal.pone.0039640, 3382133, 22745801.
22. Wouters H, Thijs V, Annemans L. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium. J Med Econ 2013, 16(3):407-414. 10.3111/13696998.2013.766200, 23320796.
23. Eckman MH, Rosan J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009, 150(2):73-83. 10.7326/0003-4819-150-2-200901200-00005, 19153410.
24. Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. PharmacoEconomics 2010, 28(1):61-74. 10.2165/11318240-000000000-00000, 20014877.
25. Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2009, 2(5):429-436. 10.1161/CIRCOUTCOMES.108.808592, 20031873.
26. You JH, Tsui KK, Wong RS, Cheng G. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin Pharmacol Ther 2009, 86(5):540-547. 10.1038/clpt.2009.104, 19571807.
27. Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 2008, 100(2):229-239.
28. Eikelboom JW, Wallantin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011, 123(21):2363-2372. 10.1161/CIRCULATIONAHA.110.004747, 21576658.
29. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, RE-COVER Study Group Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361(24):2342-2352. 10.1056/NEJMoa0906598, 19966341, RE-COVER Study Group.
30. Fihn SD, MacDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993, 118(7):511-520. 10.7326/0003-4819-118-7-199304010-00005, 8280198.
31. Fang MC, Chen J, Rich MW. Atrial fibrillation in the elderly. Am J Med 2007, 120(6):481-487. 10.1016/j.amjmed.2007.01.026, 17524745.
32. Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ 2008, 179(3):235-244. 2474869, 18663203.
33. Reynolds MW, Fahrback K, Hauch O, Wygant G, Estok R, Cella C, Nalysnyk L. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004, 126(6):1938-1945. 10.1378/chest.126.6.1938, 15596696.
34. Lafata JE, Martin SA, Kaatz S, Ward RE. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med 2000, 15(1):31-37. 10.1046/j.1525-1497.2000.01239.x, 1495325, 10632831.
35. Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, Song F. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 2007, 11(38):iii-iv. ix-66.
36. Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS, Vertrees JE, Shih MC, Holodniy M, Lavori P, THINRS Executive Committee and Site Investigators Effect of home testing of international normalized ratio on clinical events. N Engl J Med 2010, 363(17):1608-1620. 10.1056/NEJMoa1002617, 20961244, THINRS Executive Committee and Site Investigators.
37. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007, 115(21):2689-2696. 10.1161/CIRCULATIONAHA.106.653048, 17515465.
38. White R. The epidemiology of venous thromboembolism. Circulation 2003, 107(23 Suppl 1):14-18.
39. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999, 353(9162):1386-1389. 10.1016/S0140-6736(98)07534-5, 10227218.
40. Cushman M, Psaty BM, Meilahn EN, Dobs AS, Kuller LH. Post-menopausal hormone therapy and concentrations of protein C and antithrombin in elderly women. Br J Haematol 2001, 114(1):162-168. 10.1046/j.1365-2141.2001.02911.x, 11472362.
41. Régie d'assurance maladie du Québec Manuel des pharmaciens 2011, Québec: Gouvernement du Québec, Direction du service à la clientèle professionnelle. Québec, Régie d'assurance maladie du Québec.
42. Parent M, Chrétien D, Plante S. Coût de revient du suivi de la warfarine en clinique d'anticoagulothérapie. Pharmactuel 2010, 43(4):232-236.
43. Régie d'assurance maladie du Québec Manuel des médecins spécialistes 2011, Québec: RAMQ, Direction du service à la clientèle professionnelle. Québec, Régie d'assurance maladie du Québec.
44. Ministère de la santé et des services sociaux SIFO Système d'Information Financière et Opérationnelle:méthodologie 2011, Québec: Gouvernement du Québec, Direction de l'information, Ministère de la santé et des services sociaux.
45. Ministère de la santé et des services sociaux Banque de données APR-DRG (All Patient Refined Diagnosis Related Groups). Québec 2011, Québec: Gouvernement du Québec, Ministère de la santé et des services sociaux.
46. Ministère de la santé et des services sociaux Diem-Hébergement en soins de longue durée 2010, Québec: Gouvernement du Québec, Direction de la documentation. Québec, Ministère de la santé et des services sociaux.
47. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996, 156:1829-1836. 10.1001/archinte.1996.00440150083009, 8790077.
48. Sullivan PW, Arrant TW, Ellis SL, et al. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. PharmacoEconomics 2006, 24:1021-1033. 10.2165/00019053-200624100-00009, 17002484.
49. Snow V, Weiss KB, LeFevre M, McNamara R, Bass E, Green LA, Michl K, Owens DK, Susman J, Allen DI, Mottur-Pilson C, AAFP Panel on Atrial Fibrillation; ACP Panel on Atrial Fibrillation Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003, 139(12):1009-1017. 10.7326/0003-4819-139-12-200312160-00011, 14678921, AAFP Panel on Atrial Fibrillation; ACP Panel on Atrial Fibrillation.
50. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP, ESC Committee for Practice Guidelines (CPG) Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008, 29(18):2276-2315. ESC Committee for Practice Guidelines (CPG).
51. Lindsay P, Baylay M, McDonald A, Graham ID, Warner G, Phillips S. Toward a more effective approach to stroke: Canadian best practice recommendations for stroke care. CMAJ 2008, 178(11):1418-1425. 2374857, 18490636.
52. Barkun A, Bardou M, Marshall JK, Nonvariceal Upper GI Bleeding Consensus Conference Group Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003, 139(10):843-857. 10.7326/0003-4819-139-10-200311180-00012, 14623622, Nonvariceal Upper GI Bleeding Consensus Conference Group.
53. Barkun A, Fallone CA, Chiba N, Fishman M, Flook N, Martin J, Rostom A, Taylor A, Nonvariceal Upper GI Bleeding Consensus Conference Group A Canadian clinical practice algorithm for the management of patients with nonvariceal upper gastrointestinal bleeding. Can J Gastroenterol 2004, 18(10):605-609. Nonvariceal Upper GI Bleeding Consensus Conference Group.
54. Som R, Gossage JA, Crane A, Rowe PH. Surgical workload, risk factors and complications in patients on warfarin with gastrointestinal bleeding. Int J Surg 2010, 8(1):52-55. 10.1016/j.ijsu.2009.10.010, 19883802.
55. Collège des Médecins du Québec et Ordre des pharmaciens du Québec Lignes directrices-Anticoagulothérapie en milieu ambulatoire 2005, Montréal (Québec): Collège des médecins du Québec et Ordre des pharmaciens du Québec, Collège des Médecins du Québec et Ordre des pharmaciens du Québec.
56. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes 2005, London: Oxford, Oxford University Press.
57. Durand A, Gagné C, Nshimyumukiza L, Gagnon M, Rousseau F, Giguère Y, Reinharz D. Population-based simulation for public health: generic software infrastructure and its application to osteoporosis. IEEE Transactions on Systems, Man and Cybernetics, Part A: Systems and Humans 2012, 42(no 6):1396-1409.
58. Durand A, Gagné C, Gardner M-A, Rousseau F, Giguére Y. SCHNAPS: a generic population-based simulator for public health purposes. Proceedings of the 2010 Summer Simulation Multiconference July 12-14 2010, 182-189. Ottawa, ON; Canada: Summer Computer simulation Conference (SCSC.
59. Menon D, Stafinski T. Health technology assessment in Canada: 20 years strong?. Value Health 2009, 12(Suppl 2):S14-S19.
60. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation 2006, New York: Oxford University Press.
61. Sendi PP, Briggs AH. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Econ 2001, 10(7):675-680. 10.1002/hec.639, 11747050.
62. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012, 108(3):476-484. 10.1160/TH12-02-0093, 22740145.
63. Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol 2012, 31(4):330-339.
64. Kopesky S. New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence. Am J Cardiovasc Drugs 2012, 12(5):287-294.